Calliditas Therapeutics: Q4 Comment

Research Note

2021-02-18

10:17

Redeye notes that the Q4 report from Calliditas did not include any surprises. We provide a brief comment on the financials and highlight the most important events during the period. Our Base case remains at SEK250 per share - providing significant upside potential from current levels.

LS

Ludvig Svensson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.